A detailed history of Royal Bank Of Canada transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 15,000 shares of GRTS stock, worth $450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Previous 17,726 15.38%
Holding current value
$450
Previous $10,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.45 - $0.71 $1,226 - $1,935
-2,726 Reduced 15.38%
15,000 $8,000
Q2 2024

Aug 14, 2024

BUY
$0.62 - $2.35 $424 - $1,609
685 Added 4.02%
17,726 $10,000
Q1 2024

Nov 05, 2024

SELL
$1.96 - $2.9 $1,342 - $1,986
-685 Reduced 3.86%
17,041 $43,000
Q1 2024

May 15, 2024

SELL
$1.96 - $2.9 $53,619 - $79,335
-27,357 Reduced 61.62%
17,041 $43,000
Q4 2023

Feb 14, 2024

BUY
$1.28 - $2.85 $11,262 - $25,077
8,799 Added 24.72%
44,398 $90,000
Q3 2023

Nov 14, 2023

BUY
$1.19 - $2.26 $13,236 - $25,137
11,123 Added 45.44%
35,599 $61,000
Q2 2023

Aug 14, 2023

BUY
$1.66 - $3.03 $11,369 - $20,752
6,849 Added 38.86%
24,476 $47,000
Q1 2023

May 15, 2023

BUY
$2.13 - $3.74 $5,555 - $9,753
2,608 Added 17.36%
17,627 $49,000
Q4 2022

Feb 14, 2023

SELL
$2.17 - $3.92 $13,605 - $24,578
-6,270 Reduced 29.45%
15,019 $51,000
Q3 2022

Nov 14, 2022

BUY
$2.46 - $4.75 $14,978 - $28,922
6,089 Added 40.06%
21,289 $56,000
Q2 2022

Aug 15, 2022

SELL
$1.77 - $4.34 $5,356 - $13,132
-3,026 Reduced 16.6%
15,200 $36,000
Q1 2022

May 16, 2022

SELL
$4.03 - $12.19 $14,588 - $44,127
-3,620 Reduced 16.57%
18,226 $75,000
Q4 2021

Feb 14, 2022

BUY
$8.76 - $13.71 $8 - $13
1 Added 0.0%
21,846 $281,000
Q3 2021

Nov 15, 2021

BUY
$6.41 - $13.54 $13,275 - $28,041
2,071 Added 10.47%
21,845 $236,000
Q2 2021

Aug 16, 2021

BUY
$8.13 - $10.2 $160,762 - $201,694
19,774 New
19,774 $180,000

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.